Literature DB >> 9413302

Bladder dysfunction and management in multiple sclerosis.

K L Andrews1, D A Husmann.   

Abstract

Symptomatic bladder dysfunction occurs at some time in most patients with multiple sclerosis. The relapsing-remitting course and progressive loss of mobility associated with multiple sclerosis make management of urinary urgency and incontinence difficult. Urodynamic evaluation serves as a guideline for appropriate treatment. After accurate diagnosis of bladder dysfunction, a management program is developed with use of fluid schedules, voiding techniques, neuropharmacologic manipulation, intermittent catheterization, surgical treatment, and other adjunctive measures as indicated. The goals of treatment are to protect and preserve renal function, relieve symptomatic voiding dysfunction, and avoid subsequent urinary complications. A management program should be individualized, dynamic, and monitored with periodic, systematic urologic review to maintain these goals.

Entities:  

Mesh:

Year:  1997        PMID: 9413302     DOI: 10.4065/72.12.1176

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  4 in total

1.  The TRUST (EvaluaTion of Bladder Function in Relapsing-Remitting MUltiple Sclerosis Patients Treated with Natalizumab) Observational Study.

Authors:  Bhupendra O Khatri; John F Foley; Jennifer Fink; John F Kramer; Choon Cha; Xiaojun You; John D Warth; Pam Foulds
Journal:  Int J MS Care       Date:  2014

2.  Clinically isolated syndrome and multiple sclerosis: rethinking the arsenal.

Authors:  Krupa Pandey; Fred D Lublin
Journal:  Curr Treat Options Neurol       Date:  2009-05       Impact factor: 3.598

3.  The prevalence of urinary catheterization in women and men with multiple sclerosis.

Authors:  Sangeeta T Mahajan; Heidi E Frasure; Ruth Ann Marrie
Journal:  J Spinal Cord Med       Date:  2013-04-12       Impact factor: 1.985

Review 4.  Female neurogenic vesicourethral dysfunction: evaluation and management.

Authors:  Rebecca J McCrery; Rodney A Appell
Journal:  Curr Urol Rep       Date:  2005-09       Impact factor: 2.862

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.